We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-12.94%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
-$7.47M
Cap. Flow
+$285M
Cap. Flow %
20.99%
Top 10 Hldgs %
65.02%
Holding
35
New
4
Increased
13
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$72.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$71.5M
3
SRRK icon
Scholar Rock
SRRK
+$30.6M
4
MRUS
Merus
MRUS
+$26.1M
5
SLDB icon
Solid Biosciences
SLDB
+$24.9M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$18.3M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.8M
3
ALKS icon
Alkermes
ALKS
+$11.4M
4
ABVX
Abivax
ABVX
+$9.4M
5
BBOT
BridgeBio Oncology
BBOT
+$5.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
26
Neurogene
NGNE
$696M
$10.8M 0.8%
925,000
+125,000
+16% +$2.17M
TYRA icon
27
Tyra Biosciences
TYRA
$1.82B
$8.84M 0.65%
+950,000
New +$12.3M
PCSC
28
DELISTED
Perceptive Capital Solutions
PCSC
$7.72M 0.57%
750,000
– –
CELC icon
29
Celcuity
CELC
$4.03B
$7.03M 0.52%
695,650
+295,650
+74% +$3.34M
VTGN icon
30
VistaGen Therapeutics
VTGN
$9.29M
$3.94M 0.29%
1,575,000
– –
AVTX icon
31
Avalo Therapeutics
AVTX
$976M
$3.87M 0.29%
483,000
– –
ABVX
32
Abivax
ABVX
$11B
– –
-1,284,110
Closed -$9.4M
NKTX icon
33
Nkarta
NKTX
$162M
– –
-351,848
Closed -$876K
THRD
34
DELISTED
Third Harmonic Bio
THRD
– –
-237,704
Closed -$2.45M
BBOT
35
BridgeBio Oncology
BBOT
$707M
– –
-500,000
Closed -$5.25M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Commodore Capital held 35 positions worth $1.36B, down 0.55% from $1.36B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Commodore Capital deployed $285M of net new capital in Q1 2025, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Agios Pharmaceuticals: 2,185,000 shares worth $64M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Soleno Therapeutics, an estimated $18.3M trimmed.

  • Commodore Capital's largest Q1 2025 buy was Agios Pharmaceuticals: 2,185,000 shares worth $64M.
  • Commodore Capital added most to Scholar Rock in Q1 2025, an estimated $30.6M increase.
  • Commodore Capital's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $18.3M.
  • Commodore Capital fully exited Abivax in Q1 2025, selling an estimated $9.4M.
  • Commodore Capital's ten largest holdings make up 65% of its $1.36B portfolio in Q1 2025.
  • Commodore Capital opened 4 new positions and closed 4 in Q1 2025.
  • Commodore Capital's portfolio value fell 0.55% quarter-over-quarter to $1.36B.

Based on Commodore Capital's 13F filing for Q1 2025, filed 15 May 2025.